Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MUC1-C soluble decoy receptor
- Development stage
- Preclinical
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
MUC1-C soluble decoy receptor is a preclinical recombinant fusion protein consisting of the extracellular domain of the mucin 1 C-terminal subunit (MUC1-C) fused to an immunoglobulin constant (Fc) region. Developed by Genus Oncology and the Dana-Farber Cancer Institute, this decoy receptor is designed to block the function of the oncogenic MUC1-C subunit, which is aberrantly overexpressed in most human breast carcinomas and other solid tumors. By sequestering ligands or disrupting the interaction of cell-surface MUC1-C, the decoy receptor suppresses tumor cell growth and induces cell death. In preclinical models of breast cancer, treatment with the MUC1-C soluble decoy receptor demonstrated dose-dependent induction of cell death in vitro and prolonged tumor regressions in vivo.
- Other names
- MUC1-C extracellular domain-Fc fusion proteinMUC-1-C extracellular domain-Fc fusion proteinMUC 1-C extracellular domain-Fc fusion proteinMUC1-C-FcMUC-1-C-FcMUC 1-C-FcMUC1-C/ECD-Fc
02
Targets
EGFR (Epidermal growth factor receptor)LGALS3 (Galectin-3)
Beyond the preview
Go deeper on MUC1-C soluble decoy receptor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MUC1-C soluble decoy receptor.